In early November, Pfizer and its German partner, BioNtech, released results of their ongoing trial for a COVID-19 vaccine, showing very positive early results of 90% efficacy rates. Shortly after, Moderna followed suit with similarly positive results from their COVID vaccine trial. In the midst of a second wave of increasing case counts and the communal weariness from ongoing (and increasing) restrictions and lockdowns, the good news couldn’t have come soon enough. Investors around the globe were quick to hitch their wagons to the idea of a vaccine-enabled return to gatherings, events, traditional business functions and economic activity.
To continue reading please click HERE
Introduction Central bank rate announcements dominated the headlines in March. Most held steady, while pointing…
Introduction Global equity markets moved higher over the month of February. Investors held largely positive…
Introduction Global equity markets edged higher over January. Sentiment was largely mixed as investors parsed…
Introduction Investor sentiment improved in December on rising expectations that major central banks, including the…
Introduction Investor sentiment improved in December on rising expectations that major central banks, including the…
To give you information for updated tax rates, click on the link below: Essential tax…